Lisa L Catalli, NP
Nurse Practitioner · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 2
- Since medical school
- 31 years
- Graduated 1995
Offices
2 locations · Regents of the University of California · University of California San Francisco
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Lisa L Catalli’s office at (415) 476-4029 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$29,938
Medicare paid this office $29,938 for 205 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 158 | $22,996 | $97 |
| Short return visit (20+ min) | 13 | $2,352 | $48 |
| Telephone medical discussion with physician, 21-30 minutes | 19 | $1,693 | $68 |
| Return visit (30+ min) | 12 | $887 | $68 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes | 19 | $460 | $19 |
See all 8 services
| Long return visit (40+ min) | 158 | $22,996 | $97 |
| Short return visit (20+ min) | 13 | $2,352 | $48 |
| Telephone medical discussion with physician, 21-30 minutes | 19 | $1,693 | $68 |
| Return visit (30+ min) | 12 | $887 | $68 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes | 19 | $460 | $19 |
| Measurement of liver stiffness | 53 | $410 | $7 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 27 | $365 | $13 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 12 | $127 | $10 |
Who their Medicare patients are
205 Original Medicare patients in 2024. Average age 69 · Women 48% · Also on Medicaid 59% · Health risk score 2.35. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 73% · Diabetes 50% · Chronic kidney disease 31% · Coronary heart disease 22% · Depression 19% · Heart failure 16% · Cancer 14% · Atrial fibrillation 13% · COPD 10% · Dementia 6% · Stroke 5%.
The office billed $230,657, Medicare allowed $41,907 and paid $29,938; for 460 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 205 | 460 | 69 | 2.35 | $230,657 | $29,938 |
| 2023 | 166 | 297 | 68 | 2.15 | $172,664 | $22,448 |
| 2022 | 172 | 296 | 68 | 2.07 | $172,661 | $22,224 |
| 2021 | 162 | 359 | 67 | 1.94 | $206,878 | $27,679 |
| 2020 | 151 | 298 | 67 | 2.01 | $170,844 | $20,680 |
| 2019 | 116 | 173 | 66 | 2.48 | $130,877 | $13,567 |
| 2018 | 116 | 170 | 67 | 2.00 | $123,456 | $13,393 |
| 2017 | 109 | 174 | 67 | 2.46 | $112,452 | $12,709 |
| 2016 | 108 | 197 | 65 | 2.06 | $118,980 | $12,679 |
| 2015 | 134 | 194 | 65 | 1.87 | $120,303 | $12,314 |
| 2014 | 133 | 233 | 64 | 1.99 | $138,964 | $15,632 |
| 2013 | 62 | 132 | 62 | 2.30 | $68,841 | $8,308 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 131 | $19,172 | $98 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $973 | $75 |
| Measurement of liver stiffness | 46 | $318 | $7 |
2022: 3 services
| Long return visit (40+ min) | 117 | $16,680 | $102 |
| Extended patient service without direct patient contact, first hour | 31 | $2,440 | $68 |
| Measurement of liver stiffness | 42 | $327 | $8 |
2021: 6 services
| Long return visit (40+ min) | 118 | $19,343 | $103 |
| Extended patient service without direct patient contact, first hour | 21 | $1,961 | $75 |
| Short return visit (20+ min) | 11 | $1,907 | $52 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | $1,702 | $68 |
| Return visit (30+ min) | 17 | $1,227 | $68 |
| Measurement of liver stiffness | 35 | $285 | $8 |
2020: 4 services
| Long return visit (40+ min) | 109 | $14,046 | $83 |
| Telephone medical discussion with physician, 21-30 minutes | 40 | $3,257 | $59 |
| Long return visit (40+ min) | 12 | $961 | $80 |
| Measurement of liver stiffness | 27 | $289 | $11 |
2019: 1 service
| Long return visit (40+ min) | 107 | $11,643 | $80 |
2018: 2 services
| Long return visit (40+ min) | 101 | $10,980 | $79 |
| Return visit (30+ min) | 12 | $713 | $55 |
2017: 2 services
| Long return visit (40+ min) | 88 | $9,335 | $79 |
| Return visit (30+ min) | 40 | $2,572 | $56 |
2016: 3 services
| Long return visit (40+ min) | 70 | $8,310 | $78 |
| Return visit (30+ min) | 60 | $3,877 | $53 |
| Short return visit (20+ min) | 14 | $474 | $32 |
2015: 3 services
| Long return visit (40+ min) | 96 | $8,559 | $71 |
| Return visit (30+ min) | 49 | $2,689 | $51 |
| Short return visit (20+ min) | 16 | $610 | $38 |
2014: 3 services
| Long return visit (40+ min) | 90 | $10,515 | $83 |
| Return visit (30+ min) | 75 | $4,541 | $50 |
| Short return visit (20+ min) | 11 | $544 | $39 |
2013: 2 services
| Long return visit (40+ min) | 32 | $4,326 | $77 |
| Return visit (30+ min) | 42 | $3,453 | $54 |
Drugs they prescribed that Part D paid
$863,067
Pharmacies billed $863,067 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 359) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
230 generic and 129 brand-name prescriptions · $863,067 in drug cost · 32 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Sovaldi | 12 | $323,619 | $26,968 |
| Xifaxan | 32 | $112,586 | $3,518 |
| Vemlidy | 35 | $63,349 | $1,810 |
| Entecavir | 52 | $18,086 | $348 |
| Creon | 11 | $17,308 | $1,573 |
See all 10 drugs
| Sovaldi | 12 | $323,619 | $26,968 |
| Xifaxan | 32 | $112,586 | $3,518 |
| Vemlidy | 35 | $63,349 | $1,810 |
| Entecavir | 52 | $18,086 | $348 |
| Creon | 11 | $17,308 | $1,573 |
| Ribavirin | 14 | $836 | $60 |
| Azathioprine | 22 | $410 | $19 |
| Carvedilol | 62 | $220 | $4 |
| Prednisone | 20 | $130 | $7 |
| Furosemide | 21 | $67 | $3 |
Year by year
| 2024 | 359 | 69 | 0% (0) | 36% | $863,067 |
| 2023 | 244 | 49 | 0% (0) | 32% | $577,010 |
| 2022 | 201 | 49 | 0% (0) | 27% | $266,392 |
| 2021 | 267 | 51 | None | 32% | $754,652 |
| 2020 | 309 | 57 | 0% (0) | 30% | $607,715 |
| 2019 | 399 | 78 | 0% (0) | 35% | $1,552,978 |
| 2018 | 273 | 68 | 0% (0) | 38% | $1,073,409 |
| 2017 | 315 | 70 | 0% (0) | 37% | $1,769,967 |
| 2016 | 396 | 70 | 0% (0) | None | $2,772,612 |
| 2015 | 602 | 109 | None | 46% | $6,293,114 |
| 2014 | 1,071 | 124 | None | 53% | $11,844,708 |
| 2013 | 550 | 57 | None | None | $501,868 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Vemlidy | 39 | $67,746 | $1,737 |
| Entecavir | 44 | $23,535 | $535 |
| Azathioprine | 13 | $507 | $39 |
| Famotidine | 22 | $316 | $14 |
| Prednisone | 17 | $175 | $10 |
| Carvedilol | 13 | $158 | $12 |
2022: 8 drugs
| Xifaxan | 22 | $68,328 | $3,106 |
| Vemlidy | 21 | $39,164 | $1,865 |
| Entecavir | 15 | $7,855 | $524 |
| Spironolactone | 12 | $532 | $44 |
| Furosemide | 18 | $340 | $19 |
| Azathioprine | 11 | $315 | $29 |
| Prednisone | 17 | $156 | $9 |
| Carvedilol | 14 | $146 | $10 |
2021: 10 drugs
| Epclusa | 15 | $347,924 | $23,195 |
| Xifaxan | 17 | $49,848 | $2,932 |
| Vemlidy | 27 | $43,943 | $1,628 |
| Mycophenolate Mofetil | 11 | $1,299 | $118 |
| Spironolactone | 33 | $841 | $25 |
| Propranolol | 22 | $378 | $17 |
| Omeprazole | 12 | $274 | $23 |
| Furosemide | 25 | $272 | $11 |
| Prednisone | 14 | $237 | $17 |
| Carvedilol | 16 | $141 | $9 |
2020: 7 drugs
| Xifaxan | 39 | $101,901 | $2,613 |
| Vemlidy | 11 | $33,037 | $3,003 |
| Omeprazole | 31 | $458 | $15 |
| Propranolol | 24 | $449 | $19 |
| Spironolactone | 30 | $377 | $13 |
| Furosemide | 36 | $192 | $5 |
| Carvedilol | 14 | $23 | $2 |
2019: 14 drugs
| Epclusa | 19 | $503,969 | $26,525 |
| Vosevi | 19 | $467,269 | $24,593 |
| Mavyret | 12 | $159,600 | $13,300 |
| Xifaxan | 41 | $122,857 | $2,997 |
| Vemlidy | 14 | $19,668 | $1,405 |
| Kristalose | 12 | $17,259 | $1,438 |
| Ribavirin | 13 | $1,291 | $99 |
| Spironolactone | 42 | $618 | $15 |
| Lactulose | 12 | $586 | $49 |
| Propranolol | 32 | $555 | $17 |
| Omeprazole | 32 | $363 | $11 |
| Furosemide | 26 | $125 | $5 |
| Famotidine | 20 | $94 | $5 |
| Carvedilol | 12 | $79 | $7 |
2018: 11 drugs
| Epclusa | 12 | $296,664 | $24,722 |
| Mavyret | 16 | $211,023 | $13,189 |
| Xifaxan | 28 | $71,361 | $2,549 |
| Vemlidy | 15 | $23,260 | $1,551 |
| Kristalose | 20 | $11,762 | $588 |
| Lactulose | 16 | $432 | $27 |
| Spironolactone | 24 | $267 | $11 |
| Propranolol | 13 | $238 | $18 |
| Omeprazole | 17 | $220 | $13 |
| Ciprofloxacin | 13 | $85 | $7 |
| Furosemide | 14 | $74 | $5 |
2017: 13 drugs
| Epclusa | 34 | $843,025 | $24,795 |
| Zepatier | 11 | $201,411 | $18,310 |
| Mavyret | 15 | $199,142 | $13,276 |
| Xifaxan | 22 | $45,128 | $2,051 |
| Ribavirin | 11 | $1,530 | $139 |
| Propranolol | 26 | $323 | $12 |
| Omeprazole | 33 | $233 | $7 |
| Spironolactone | 33 | $221 | $7 |
| Azathioprine | 12 | $176 | $15 |
| Ciprofloxacin | 15 | $99 | $7 |
| Trazodone | 12 | $78 | $7 |
| Quetiapine | 11 | $75 | $7 |
| Furosemide | 16 | $54 | $3 |
2016: 13 drugs
| Harvoni | 43 | $1,345,334 | $31,287 |
| Epclusa | 18 | $449,552 | $24,975 |
| Sovaldi | 15 | $412,263 | $27,484 |
| Xifaxan | 18 | $33,239 | $1,847 |
| Entecavir | 20 | $9,293 | $465 |
| Ribavirin | 28 | $3,758 | $134 |
| Omeprazole | 40 | $338 | $8 |
| Spironolactone | 23 | $202 | $9 |
| Azathioprine | 12 | $183 | $15 |
| Furosemide | 34 | $157 | $5 |
| Ciprofloxacin | 14 | $119 | $8 |
| Famotidine | 19 | $96 | $5 |
| Quetiapine | 14 | $84 | $6 |
2015: 15 drugs
| Harvoni | 159 | $5,014,781 | $31,540 |
| Sovaldi | 26 | $735,687 | $28,296 |
| Xifaxan | 40 | $65,692 | $1,642 |
| Entecavir | 15 | $13,521 | $901 |
| Ribavirin | 32 | $3,394 | $106 |
| Ribasphere | 27 | $3,165 | $117 |
| Lactulose | 17 | $537 | $32 |
| Omeprazole | 50 | $437 | $9 |
| Azathioprine | 13 | $328 | $25 |
| Furosemide | 30 | $277 | $9 |
| Generlac | 14 | $255 | $18 |
| Spironolactone | 20 | $224 | $11 |
| Ciprofloxacin | 24 | $194 | $8 |
| Propranolol | 22 | $184 | $8 |
| Citalopram Hbr | 14 | $67 | $5 |
2014: 21 drugs
| Sovaldi | 249 | $6,966,784 | $27,979 |
| Olysio | 150 | $3,320,214 | $22,135 |
| Harvoni | 39 | $1,256,254 | $32,212 |
| Pegasys | 22 | $68,965 | $3,135 |
| Xifaxan | 43 | $65,992 | $1,535 |
| Pegasys Proclick | 12 | $37,819 | $3,152 |
| Ribapak | 32 | $33,571 | $1,049 |
| Ribavirin | 124 | $13,404 | $108 |
| Ribasphere | 25 | $4,870 | $195 |
| Propranolol Hcl Er | 11 | $882 | $80 |
| Omeprazole | 69 | $783 | $11 |
| Lactulose | 16 | $601 | $38 |
| Spironolactone | 15 | $296 | $20 |
| Generlac | 14 | $254 | $18 |
| Prednisone | 14 | $242 | $17 |
| Propranolol | 37 | $238 | $6 |
| Citalopram Hbr | 28 | $198 | $7 |
| Ondansetron | 11 | $174 | $16 |
| Triamcinolone Acetonide | 17 | $165 | $10 |
| Ciprofloxacin | 15 | $161 | $11 |
| Furosemide | 16 | $65 | $4 |
2013: 13 drugs
| Procrit | 35 | $122,024 | $3,486 |
| Pegasys | 26 | $73,546 | $2,829 |
| Pegasys Proclick | 22 | $61,789 | $2,809 |
| Ribasphere | 18 | $4,237 | $235 |
| Ribavirin | 13 | $2,715 | $209 |
| Omeprazole | 90 | $1,100 | $12 |
| Spironolactone | 26 | $868 | $33 |
| Propranolol | 45 | $639 | $14 |
| Gabapentin | 14 | $452 | $32 |
| Triamcinolone Acetonide | 17 | $285 | $17 |
| Ciprofloxacin | 20 | $268 | $13 |
| Citalopram Hbr | 28 | $176 | $6 |
| Furosemide | 29 | $157 | $5 |
Money from drug and device companies
$1,155 in 2025
| 2025 | 1 | 1 | $1,155 | $1,155 |
| 2024 | 1 | 3 | $1,700 | $1,813 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novo Nordisk | None | $1,155 | 1 payment
|
See the published payment
| Novo Nordisk | Consulting · 2025-10-10 | None | $1,155 |
See earlier years (2024)
2024: $1,813
| Madrigal Pharmaceuticals | Rezdiffra | $1,813 | 3 payments
|
Professional record
- NPI
- 1184941791
- Licence
- CA 492418
- Group
- Regents of the University of California · University of California San Francisco
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LA2200X (363LA2200X)
- Mailing address
- 350 Parnassus, Suite 410, San Francisco, CA, 94143
- NPI first listed
- 2010-04-23
- NPI last updated
- 2010-04-23
This is when the NPI record was last certified, not a medical board exam.